Related Experiment Video
Updated: Jul 23, 2026

A Protocol for Transcranial Photobiomodulation Therapy in Mice
Published on: November 18, 2018
Supplementation of Regular Diet With Medium-Chain Triglycerides for Procognitive Effects: A Narrative Review
Ksenia Shcherbakova1, Alexander Schwarz2, Sergey Apryatin1
1I.P. Pavlov Department of Physiology, Institute of Experimental Medicine, Saint Petersburg, Russia.
Abstract:
It is now widely accepted that ketosis (a physiological state characterized by elevated plasma ketone body levels) possesses a wide range of neuroprotective effects. There is a growing interest in the use of ketogenic supplements, including medium-chain triglycerides (MCT), to achieve intermittent ketosis without adhering to a strict ketogenic diet. MCT supplementation is an inexpensive and simple ketogenic intervention, proven to benefit both individuals with normal cognition and those suffering from mild cognitive impairment, Alzheimer's disease, and other cognitive disorders. The commonly accepted paradigm underlying MCT supplementation trials is that the benefits stem from ketogenesis and that MCT supplementation is safe. However, medium-chain fatty acids (MCFAs) may also exert effects in the brain directly. Moreover, MCFAs, long-chain fatty acids, and glucose participate in mutually intertwined metabolic pathways. Therefore, the metabolic effects must be considered if the desired procognitive effects require administering MCT in doses larger than 1 g/kg. This review summarizes currently available research on the procognitive effects of using MCTs as a supplement to regular feed/diet without concomitant reduction of carbohydrate intake and focuses on the revealed mechanisms linked to particular MCT metabolites (ketone bodies, MCFAs), highlighting open questions and potential considerations.
Related Concept Videos
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Lipids: Dietary Sources and Requirements
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Atherosclerosis III: Management

